Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cue Biopharma granted inducement equity awards to seven new employees, including its newly appointed CEO, Shao-Lee Lin, as part of its 2026 Inducement Stock Incentive Plan. Dr. Lin received a non-statutory stock option to purchase 655,074 shares at $30.42 per share and fully vested restricted stock units for 327,537 shares.
Key figures
- Offering Price
- 30.42
- Shares Offered
- 655074
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.